News Releases

Latest News Releases

Dec 18, 2024
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Download
Facebook Twitter LinkedIn Email this page
Nov 05, 2024
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
Download
Facebook Twitter LinkedIn Email this page
Oct 09, 2024
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
Download
Facebook Twitter LinkedIn Email this page
Sep 24, 2024
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
Download
Facebook Twitter LinkedIn Email this page
Sep 06, 2024
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
Download
Facebook Twitter LinkedIn Email this page
Aug 13, 2024
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
Download
Facebook Twitter LinkedIn Email this page
Jun 24, 2024
Entrada Therapeutics Announces $100 Million Registered Direct Offering
Download
Facebook Twitter LinkedIn Email this page
Jun 24, 2024
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
Download
Facebook Twitter LinkedIn Email this page
Jun 03, 2024
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Download
Facebook Twitter LinkedIn Email this page
May 16, 2024
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Download
Facebook Twitter LinkedIn Email this page

Quick access to common resources

Frequently Asked Questions Frequent questions about owning stock in Entrada. SEC Filings View current and past SEC filings in various easy-to-access file formats. Events & Presentation View our latest events and presentation.